New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cance...(l data were used which allowed the ...),Health

allowed the conduct of more robust overall analysis and sub-analyses of

groups of special interest, such as those with haemoglobin (Hb) less#

than 11 g/dL.

- It included all 12 prospective, randomised, controlled studies in which

NeoRecormon was compared to placebo or standard treatment

(transfusions, if required) in patients with cancer undergoing

treatment with chemotherapy (7 studies), surgery (2 studies),

radiotherapy (2 studies) or radio-chemotherapy (1 study).

Since NeoRecormon was introduced nearly two decades ago, it has had an established safety and efficacy track record. Studies have confirmed that within its approved licence NeoRecormon has been shown to reduce the need for blood transfusions and to significantly improve quality of life for anaemic patients with cancer being treated with chemotherapy (2)(3)(4).

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Additional information about the Roche Group is available on the Internet at http://www.roche.com.

References

(1) Br J Cancer advance online publication 10 June 2008;

doi:10.1038/sj.bjc.6604408

(2) Br J Cancer. 2003 Apr 7;88(7):988-95

(3) Cancer Chemother Pharmacol. 2007 Jan;59(1):35-42

(4) J Clin Oncol. 2002 May 15;20(10):2486-94